ClinicalTrials.gg
CompletedNCT05689931Updated Nov 5, 2026Results posted

Blood Leukocyte Profiling in Eosinophilic Type 2 Asthma: Influence of Systemic IL-5 Targeting

An observational study in Asthma, sponsored by Region Skane. Completed at 1 site in Sweden. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Region Skane · Observational

How we know

Updated Nov 5, 2026Now CompletedResults posted+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
37
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 93 studies in Asthma with a site in Sweden — 6 open to participants now, 11 under way, none of them phase 3. Asthma · Sweden.

Enrollment
12th of 12
37 · median 1,231
Started
2019
with 3 others
Observational
12 of 93
1 open now
Registered
83rd of 93
by date
Lead sponsor
2 of 93
Region Skane

Among the 93 studies in Asthma with a site in Sweden, this one is the 12th largest by enrollment of the 12 observational ones that give a count, is one of 4 that started in 2019, is one of 12 observational ones, and was the 83rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 93 studies in Asthma with a site in Sweden are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Asthma with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this exploratory and observational prospective study is to study the composition and phenotypes of blood leukocytes collected from asthmatic patients before and after instantiated treatment with the interleukin-5 neutralizing antibody mepolizumab. Comparisons will be made to leukocyte profiles in patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.

Read the detailed description

Asthma is a chronic inflammatory and obstructive condition affecting the airways. The disease is commonly associated with elevated blood eosinophils and tissue eosinophilia. Many aspects of the pathophysiological mechanisms and clinical symptoms are controlled by conventional therapies such as inhaled corticosteroids (ICS) and long acting β2 agonists. However, some patients remain clinically uncontrolled and need additional treatment such as direct targeting of eosinophil granulocytes by neutralizing the eosinophil-promoting cytokine interleukin 5 (IL5). Mepolizumab is a humanized monoclonal IL-5 neutralizing antibody that is used to treat patients with moderate-severe eosinophilic asthma. While a marked reduction of eosinophils is a key effect of mepolizumab, the exact mechanism of action is unknown. Apart from basophils, that also express the receptor for IL-5, other leukocytes are likely to be indirectly affected by the suppressed eosinophilia. In addition, it is largely unknown to what extent the few eosinophils remaining after anti-IL5 treatment differ from pre-treatment eosinophils.

The present study is a prospective observational asthma study that aims to use microscopic analysis to investigate the composition and subtypes of blood leukocytes collected before and after instantiated mepolizumab treatment. Comparisons are made to patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All asthma patients will be recruited at the Department of Allergology and Lung Medicine, Skåne University Hospital (SUS), Lund, Sweden. Healthy control subjects are recruited by local advertisement.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of asthma (the asthma patient arms)
  • Eligible for Mepolizumab treatment as per the country-specific prescribing information (the arms with Mepolizumab)

Exclusion criteria

Exclusion criteria:

  • Any diagnosed infection (all arms)
  • Previous history of lung disease, chronic inflammatory condition, atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling (Healthy non-asthma control subjects)
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
37 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Asthma patients initiating Mepolizumab treatment

    Patients will be selected on the standard criteria used to select eligible asthma patients for mepolizumab treatment (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients may be included. Exclusion criteria: any infection

    Biological: Mepolizumab · Drug: Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

  • Asthma patients already on Mepolizumab treatment

    Patients that have been selected and given Mepolizumab treatment for \> 4 months according to standard eligible and treatment regimen criteria (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients that have been on Mepolizumab treatment for \> 4 weeks will be included. Exclusion criteria: any infections

    Biological: Mepolizumab · Drug: Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

  • Asthma patients without Mepolizumab treatment

    Inclusion: Asthma patients without any biological (antibody-based) treatment but on routine ICS and LABA treatment as part of their normal care. Exclusion criteria are any infections

    Drug: Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

  • Healthy non-asthmatic control subjects

    Exclusion criteria: previous history of lung disease, chronic inflammatory condition, or atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling

Interventions

  • BiologicalMepolizumab

    Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma. Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

    Also known as: Mepolizumab (brand name: Nucala)

  • DrugStandard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

    Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

    Also known as: ICS and LABA

06

What researchers measure

Primary outcomes

  1. Change in Blood Eosinophil Marker Expression

    Quantitative analysis of low-intensity proMBP-positive eosinophil-lineage proxy cells in FFPE blood leukocyte pellet sections

    Time frame: Baseline, Day 2, and Month 4 after mepolizumab initiation

  2. Change in Blood Basophil Marker Expression

    Quantitative analysis of high-intensity proMBP-positive basophil-like cells in FFPE blood leukocyte pellet sections.

    Time frame: Baseline, Day 2, and Month 4 after mepolizumab initiation

  3. Change in Blood Leukocyte Composition

    Relative proportion of low-/mid-intensity proMBP-positive eosinophil-lineage proxy cells within the proMBP panel in FFPE blood leukocyte pellet sections

    Time frame: Baseline, Day 2, and Month 4 after mepolizumab initiation

Secondary outcomes

  1. Change in Blood T Lymphocyte Marker Expression

    Quantitative CD4 Th-axis balance readout in FFPE blood leukocyte pellet sections, expressed as log2(GATA3/T-bet ratio).

    Time frame: Baseline, Day 2, and Month 4 after mepolizumab initiation

  2. Change in Blood B Lymphocyte Marker Expression

    Quantitative B-cell HLA-DR readout in FFPE blood leukocyte pellet sections, expressed as the percentage of HLA-DR-positive cells within the CD19/CD20-gated population.

    Time frame: Baseline, Day 2, and Month 4 after mepolizumab initiation

  3. Leukocyte Total Cell Counts

    Routine clinical laboratory total leukocyte counts in peripheral blood

    Time frame: Baseline, Day 2, and Month 4 after mepolizumab initiation.

Other outcomes

  1. Change in Forced Expiratory Volume in 1 Second (FEV1)

    Spirometry: Forced Expiratory Volume, 1s; (FEV1).

    Time frame: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.

  2. Change in Forced Vital Capacity (FVC)

    Spirometry: Forced Vital Capacity (FVC)

    Time frame: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.

  3. Change in Exhaled FeNo

    Fractional exhaled NO will be measured at multiple flows

    Time frame: Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.

07

Results

Posted Nov 5, 2026
Limitations and caveats
Final enrollment was lower than planned due to COVID-19-related restrictions, post-pandemic delays in restarting clinical research, and reduced clinical use of mepolizumab as other T2-high asthma biologics became more common. The mepolizumab-initiation cohort was therefore small (n=5), limiting statistical power. Results are exploratory.Some originally listed routine hematology outcomes are not reported separately because the final analysis dataset focused on histology-based leukocyte analyses.

Participant flow

Recruitment and follow-up were substantially affected by COVID-19-related restrictions and post-pandemic delays in restarting clinical research. In addition, clinical use of mepolizumab decreased over time as other biologics for type 2-high asthma became more commonly used. These factors reduced the number of eligible mepolizumab initiators during the study period.

Participant flow — Overall Study
MilestoneGroup 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy Controls
Started5101111
Completed5101111
Not completed0000

Outcome measures

PrimaryChange in Blood Eosinophil Marker Expression

Quantitative analysis of low-intensity proMBP-positive eosinophil-lineage proxy cells in FFPE blood leukocyte pellet sections

Time frame:
Baseline, Day 2, and Month 4 after mepolizumab initiation
Reported as:
Mean · Cells per section
Change in Blood Eosinophil Marker Expression
Cells per sectionGroup 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy Controls
Baseline274.8 (74 to 490)———
Day 248.6 (12 to 99)———
Month 439.2 (1.0 to 63.0)———
PrimaryChange in Blood Basophil Marker Expression

Quantitative analysis of high-intensity proMBP-positive basophil-like cells in FFPE blood leukocyte pellet sections.

Time frame:
Baseline, Day 2, and Month 4 after mepolizumab initiation
Reported as:
Mean · Cells per section
Change in Blood Basophil Marker Expression
Cells per sectionGroup 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy Controls
Baseline52.8 (12 to 125)———
Day 217.8 (2 to 62)———
Month 419.8 (5 to 45)———
PrimaryChange in Blood Leukocyte Composition

Relative proportion of low-/mid-intensity proMBP-positive eosinophil-lineage proxy cells within the proMBP panel in FFPE blood leukocyte pellet sections

Time frame:
Baseline, Day 2, and Month 4 after mepolizumab initiation
Reported as:
Mean · Proportion of proMBP panel
Change in Blood Leukocyte Composition
Proportion of proMBP panelGroup 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy Controls
Baseline0.0318 (0.0087 to 0.0514)———
Day 20.0339 (0.0044 to 0.0649)———
Month 40.0118 (0.0013 to 0.0252)———
SecondaryChange in Blood T Lymphocyte Marker Expression

Quantitative CD4 Th-axis balance readout in FFPE blood leukocyte pellet sections, expressed as log2(GATA3/T-bet ratio).

Time frame:
Baseline, Day 2, and Month 4 after mepolizumab initiation
Reported as:
Mean · log2 ratio
Change in Blood T Lymphocyte Marker Expression
log2 ratioGroup 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy Controls
Baseline2.946 (1.802 to 6.147)———
Day 20.862 (-0.168 to 2.422)———
Month 42.075 (0.000 to 4.621)———
SecondaryChange in Blood B Lymphocyte Marker Expression

Quantitative B-cell HLA-DR readout in FFPE blood leukocyte pellet sections, expressed as the percentage of HLA-DR-positive cells within the CD19/CD20-gated population.

Time frame:
Baseline, Day 2, and Month 4 after mepolizumab initiation
Reported as:
Mean · Percent of CD19/CD20-gated cells
Change in Blood B Lymphocyte Marker Expression
Percent of CD19/CD20-gated cellsGroup 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy Controls
Baseline61.857 (50.909 to 69.643)———
Day 242.465 (12.560 to 65.217)———
Month 425.132 (3.774 to 47.826)———
SecondaryLeukocyte Total Cell Counts

Routine clinical laboratory total leukocyte counts in peripheral blood

Time frame:
Baseline, Day 2, and Month 4 after mepolizumab initiation.
Reported as:
Mean · 10^9 cells/L
Leukocyte Total Cell Counts
10^9 cells/LGroup 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy Controls
Baseline8.16 (6 to 10.9)———
Day 27.56 (5.2 to 10.6)———
Month 48.52 (5.1 to 11.4)———
Other pre-specifiedChange in Forced Expiratory Volume in 1 Second (FEV1)

Spirometry: Forced Expiratory Volume, 1s; (FEV1).

Time frame:
Change from baseline at 4 weeks, and 4 months after initiated biological treatment.

Results for this outcome have not been posted.

Other pre-specifiedChange in Forced Vital Capacity (FVC)

Spirometry: Forced Vital Capacity (FVC)

Time frame:
Change from baseline at 4 weeks, and 4 months after initiated biological treatment.

Results for this outcome have not been posted.

Other pre-specifiedChange in Exhaled FeNo

Fractional exhaled NO will be measured at multiple flows

Time frame:
Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.

Results for this outcome have not been posted.

Adverse events

Collected over From enrollment through Month 4 follow-up for Group 1; from enrollment through the 1-week post-refill follow-up for Group 2; and during the baseline study visit for Groups 3 and 4. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: T2-high Asthma Initiating Mepolizumab0/5 (0%)0/5 (0%)0/5 (0%)
Group 2: T2-high Asthma on Maintenance Mepolizumab0/10 (0%)0/10 (0%)0/10 (0%)
Group 3: Moderate-severe Asthma Not Eligible for Biologics0/11 (0%)0/11 (0%)0/11 (0%)
Group 4: Healthy Controls0/11 (0%)0/11 (0%)0/11 (0%)

Baseline characteristics

Baseline characteristics were summarized across four observational study groups: T2-high asthma patients initiating mepolizumab, T2-high asthma patients on maintenance mepolizumab, severe asthma patients not eligible for biologics, and healthy controls.

Age, Continuous
Age, Continuous(Years)Group 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy ControlsTotal
Median62 (40 to 74)69 (61 to 76)51 (38 to 67)47 (40 to 54)57 (38 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy ControlsTotal
Female359926
Male252211
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Group 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy ControlsTotal
Count of participants————0
BMI
BMI(kg/m2)Group 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy ControlsTotal
Median26.6 (24.3 to 30.8)28.3 (25.9 to 37.1)28.4 (22.4 to 32.9)23.8 (20.7 to 26.5)26.8 (20.7 to 37.1)
FEV1 % predicted
FEV1 % predicted(Percent predicted)Group 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy ControlsTotal
Median76 (52 to 85)66 (54 to 84)84 (69 to 91)101 (92 to 107)82 (52 to 107)
FEV1/FVC
FEV1/FVC(Ratio)Group 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy ControlsTotal
Median0.7 (0.59 to 0.83)0.58 (0.5 to 0.71)0.69 (0.57 to 0.81)0.75 (0.72 to 0.79)0.68 (0.5 to 0.83)
ACT score
ACT score(points)Group 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy ControlsTotal
Median15 (10 to 20)21 (19 to 24)15 (14 to 21)25 (25 to 25)18 (10 to 25)
Smoking status
Smoking status(Participants)Group 1: T2-high Asthma Initiating MepolizumabGroup 2: T2-high Asthma on Maintenance MepolizumabGroup 3: Moderate-severe Asthma Not Eligible for BiologicsGroup 4: Healthy ControlsTotal
Never3461023
Former265114

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • The Lung and Allergy Clinic, Skåne University Hospital (SUS)
    Lund, Skåne County 22185, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2019 to primary completion in Sep 2025, 80 months.

Results were first posted in Nov 2026, 1 year 2 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Feb 2023 → Jan 2019, primary completion Apr 2024 → Sep 2025 and completion Dec 2024 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2022
First posted
Jan 19, 2023
StartActual
Jan 1, 2019was Feb 2023
Primary completionActual
Sep 1, 2025was Apr 2024
CompletionActual
Dec 18, 2025was Dec 2024
Results first posted
Nov 5, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 5, 2026
Results
Results posted
posted Nov 5, 2026
Sites
1 site added, 1 site removed
Show site
  • The Lung and Allergy Clinic, Skåne University Hospital (SUS) · Lund, Sweden
Show 1 removed
  • The Lung and Allergy Clinic, Skåne University Hospital (SUS) · Lund, Sweden
Nov 5, 2026
Start date
Feb 1, 2023→Jan 1, 2019 (actual)
Nov 5, 2026
Primary completion
Apr 1, 2024→Sep 1, 2025 (actual)
Nov 5, 2026
Study completion
Dec 18, 2024→Dec 18, 2025 (actual)
Nov 5, 2026
Enrollment
80 (estimated)→37 (actual)
Nov 5, 2026
Primary outcomes
3 time frame changed, 3 description edited
What changed in the outcomes
  • Time frameChange in Blood Eosinophil Marker ExpressionChange from baseline at 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment → Baseline, Day 2, and Month 4 after mepolizumab initiation
  • Time frameChange in Blood Basophil Marker ExpressionChange from baseline at 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment → Baseline, Day 2, and Month 4 after mepolizumab initiation
  • Time frameChange in Blood Leukocyte CompositionChange from baseline at 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment → Baseline, Day 2, and Month 4 after mepolizumab initiation
  • DescriptionChange in Blood Basophil Marker Expression: how it is measured was reworded
  • DescriptionChange in Blood Eosinophil Marker Expression: how it is measured was reworded
  • DescriptionChange in Blood Leukocyte Composition: how it is measured was reworded
Nov 5, 2026
Secondary outcomes
1 edited, 3 time frame changed, 3 description edited
What changed in the outcomes
  • Time frameChange in Blood T Lymphocyte Marker ExpressionChange from baseline at 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment → Baseline, Day 2, and Month 4 after mepolizumab initiation
  • Time frameChange in Blood B Lymphocyte Marker ExpressionChange from baseline at 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment → Baseline, Day 2, and Month 4 after mepolizumab initiation
  • Time frameLeukocyte Total Cell CountsChange from baseline at 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment → Baseline, Day 2, and Month 4 after mepolizumab initiation.
  • DescriptionChange in Blood B Lymphocyte Marker Expression: how it is measured was reworded
  • DescriptionChange in Blood T Lymphocyte Marker Expression: how it is measured was reworded
  • DescriptionLeukocyte Total Cell Counts: how it is measured was reworded
  • Editedother outcomeChange in Forced Expiratory Volume in 1 secondSecond (FEV1)Time frame: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Status unknown→Completed
    Results posted
    1 site added, 1 site removed
    Show site
    • The Lung and Allergy Clinic, Skåne University Hospital (SUS) · Lund, Sweden
    Show 1 removed
    • The Lung and Allergy Clinic, Skåne University Hospital (SUS) · Lund, Sweden
    Start date Feb 1, 2023→Jan 1, 2019 (now actual)
    Primary completion Apr 1, 2024→Sep 1, 2025 (now actual)
    Study completion Dec 18, 2024→Dec 18, 2025 (now actual)
    Enrollment 80 (estimated)→37 (actual)
    Primary outcomes 3 time frame changed, 3 description edited
    What changed in the outcomes
    • Time frameChange in Blood Eosinophil Marker ExpressionChange from baseline at 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment → Baseline, Day 2, and Month 4 after mepolizumab initiation
    • Time frameChange in Blood Basophil Marker ExpressionChange from baseline at 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment → Baseline, Day 2, and Month 4 after mepolizumab initiation
    • Time frameChange in Blood Leukocyte CompositionChange from baseline at 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment → Baseline, Day 2, and Month 4 after mepolizumab initiation
    • DescriptionChange in Blood Basophil Marker Expression: how it is measured was reworded
    • DescriptionChange in Blood Eosinophil Marker Expression: how it is measured was reworded
    • DescriptionChange in Blood Leukocyte Composition: how it is measured was reworded
    Secondary outcomes 1 edited, 3 time frame changed, 3 description edited
    What changed in the outcomes
    • Time frameChange in Blood T Lymphocyte Marker ExpressionChange from baseline at 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment → Baseline, Day 2, and Month 4 after mepolizumab initiation
    • Time frameChange in Blood B Lymphocyte Marker ExpressionChange from baseline at 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment → Baseline, Day 2, and Month 4 after mepolizumab initiation
    • Time frameLeukocyte Total Cell CountsChange from baseline at 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment → Baseline, Day 2, and Month 4 after mepolizumab initiation.
    • DescriptionChange in Blood B Lymphocyte Marker Expression: how it is measured was reworded
    • DescriptionChange in Blood T Lymphocyte Marker Expression: how it is measured was reworded
    • DescriptionLeukocyte Total Cell Counts: how it is measured was reworded
    • Editedother outcomeChange in Forced Expiratory Volume in 1 secondSecond (FEV1)Time frame: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05689931
Lead sponsor
Region Skane
Collaborators
Lund University
Responsible party
Sponsor
First posted
Jan 19, 2023
Start date
Jan 1, 2019
Primary completion
Sep 1, 2025
Completion
Dec 18, 2025
Results posted
Nov 5, 2026
Last update
Nov 5, 2026

Study contacts

Jonas Erjefält
principal investigator · Lund University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion